There is currently concern about the short term risk of adverse outcomes, particularly death, in Background -There is concern about an increase in deaths from respiratory causes patients with increasing asthma severity who are started on additional asthma therapy. [1][2][3] in asthma patients using long acting agonists. According to the guidelines of An observational study based on the General Practice Research Database (GPRD) was the British Thoracic Society, long acting agonists, ipratropium bromide, and therefore performed to examine the use of drugs recommended for increasingly symptomatic theophylline should be used to treat patients with increasing asthma severity asthma patients and to estimate the short term pulmonary death rates in this population in who are already receiving treatment with short acting agonists and inhaled ster-relation to the last prescribed asthma drug.
Recording of deaths is virtually complete in asthma in the year prior to the index date (in four three-monthly intervals), (5) drug treatthe GPRD. The annual death rate derived from this database is 10.8 and 10.5 per 1000 people ment for asthma at the index date (no treatment, agonist, inhaled or oral steroid, actively enrolled in 1992 and 1993, respectively. These rates are closely similar to the agonist and steroid combined, other asthma drugs), (6) body mass index (BMI) (<25, 25-rate of 11.0 per 1000 derived from available UK data. 9 29.9, 30+ kg/m 2 , unknown), and (7) smoking status (current, ex-smoker, non-smoker, unknown) .
       From the computer-recorded clinical records  - 
To compare the risks of death in the three we identified all persons aged 12-64 years with a diagnosis of asthma who received a first time exposure groups a separate and independent nested case-control analysis was performed, prescription for salmeterol, ipratropium bromide (including the nebulised form), or theo-adjusting for the above mentioned indicators of asthma severity. For this purpose, we idenphylline (or aminophylline) between 1 January 1992 and 30 April 1995. Subjects had to have tified the subjects who had died from a pulmonary cause (cases) and compared their drug a computer-recorded prescription history of at least six months' duration prior to the index exposure with that of a group of control patients derived from the base population who had date (the date of first prescription) in order to be eligible to participate in the study. Patients survived. Cases were matched to six controls by age, sex, and calendar time (year of first with a diagnosis of cystic fibrosis were excluded from the study population.
prescription for a study drug). The same variables were assessed as those which were used The study patients were followed for exactly 112 days (16 weeks) after receiving a first pre-to describe the entire base population (see above) and were included in the regression scription for one of the three study drugs of interest and all deaths which occurred in this analysis. The control subjects for the nested case-control analysis were selected randomly time period were identified. We distinguished between respiratory deaths, deaths from cardio-from the base population (described above).
Relative risk estimates (odds ratios), adjusted vascular diseases, cancer deaths, and deaths from other causes, and death certificates for for the variables noted above, were obtained by conditional logistic regression (SAS). patients who had died from respiratory and cardiovascular diseases were examined individually. If a patient had more than one primary cause of death on the death certificate Results       the respiratory cause was given precedence over a non-respiratory cause.
A total of 14 657 patients took part in the study, 6725 in the salmeterol group, 2937 in the The number of deaths from respiratory causes at 16 weeks was estimated separately ipratropium bromide group, and 2973 in the theophylline group who received a first time for the salmeterol, ipratropium bromide, and theophylline cohorts. Subjects who received prescription for this one study drug only during the study period. In addition, 1135 subjects one of the study drugs and did not die within 112 days of first use may have received another received a first time prescription for more than one study drug with an interval of more than study drug subsequently. Such subjects could contribute person-time to more than one study 112 days, therefore contributing person-time to more than one drug group, and 887 subjects cohort.
received a first time prescription for a second or third study drug within 112 days of the first time prescription of the first study drug.             A total of 8386 asthma patients contributed 112 days of follow up time of salmeterol use,  In order to assess patient characteristics and 4305 patients of ipratropium bromide use, and 4228 of theophylline use. Since each patient indicators for the severity of asthma in the entire study population according to study drug, a was followed for four months, the salmeterol group represents 2795.3 person-years, the detailed analysis of a random sample of 100 patients with at least 12 months of prior re-ipratropium group 1435 person-years, and the theophylline group 1409.3 person-years of corded drug use was performed for each of the three cohorts. Variables evaluated for each follow up.
Overall, there were 70 deaths in the study study drug cohort were (1) duration of asthma prior to the date of first prescription for a population within 112 days of follow up after the first prescription of one of the three study study drug (<12, 12-24, 25-60, >60 months, unknown) , (2) the presence of other respiratory drugs, 28 (40%) of which were due to respiratory disease. The causes of death in the diagnoses in the patient history besides asthma (chronic obstructive pulmonary disease three drug groups, summarised according to categories (respiratory deaths, cardiovascular (COPD) or emphysema), (3) the number of outpatient visits (0, 1-4, >4) and whether or deaths, cancer deaths, other causes), are listed in table 1. not the patient had been admitted to hospital due to asthma in the year prior to the index There were five deaths from respiratory disease in the salmeterol group (all men; one <55 date, (4) the number of drug prescriptions for phylline; users of ipratropium were sub- However, admission to hospital for asthma in the year prior to use was more frequent in the * More than one study drug started during the 16-week period of follow up (four deaths ipratropium bromide and theophylline, one death ipratropium bromide and salmeterol) ipratropium group (20%) than in the salmeterol † The cause of death was unascertainable for one subject in the salmeterol group.
(12%) and theophylline groups (6%) (table 2).
years, three aged 55-59 years, and one aged       60-64 years), 14 in the ipratropium bromide Use of a agonist (77%) prior to the index group (five men; six aged <55 years, three aged date was similar in the three groups (range 55-59, and five aged 60-64 years), and four in 76-78%; table 3). However, the use of inhaled the theophylline group (two men; one aged steroids was higher in the salmeterol group <55 years and three aged 60-64 years). Five (93%) than in the theophylline (73%) or iprapatients died after receiving a first time pre-tropium groups (63%). In the three groups scription for two study drugs of interest within combined about 80% of subjects used at least 112 days before death (two men; two aged <55 two drugs for asthma prior to the index date. In years, two aged 55-59 years, and one aged the salmeterol group the percentage of patients 60-64 years). Four were treated with ipra-receiving both a short acting agonist and tropium and theophylline, and one with ipra-steroids was higher (77%) than for ipratropium tropium and salmeterol (table 1). The crude bromide (61%) and theophylline (66%). The death rates were 1.8/1000 person-years, 9.8/ number of prescriptions for asthma drugs in-1000 person-years, and 2.8/1000 person-years creased substantially during the 12 months for users of salmeterol, ipratropium bromide prior to the index date (table 3) . and theophylline alone, respectively.
There were five cardiovascular deaths in the salmeterol group (crude death rate 1.8/1000 per-   son-years), eight in the ipratropium bromide Of the subjects who died from a respiratory group (5.6/1000 person-years), and seven in the cause, 21 of 28 (75%) had a prior diagnosis of theophylline group (5.0/1000 person-years).
COPD or emphysema. Demographic variables and indicators for the severity of asthma for the 28 respiratory deaths are described in table             4. The severity of the respiratory condition of the subjects who died compared with the three  The age distribution of the three study cohorts samples of 100 cohort subjects is reflected in a higher use of asthma drugs and a distinct was similar for users of salmeterol and theo- Age and sex distributions represent the entire cohort. The other parameters represent a random sample of 100 subjects (absolute numbers are therefore percentages). * Prior to the index date. † Due to the respiratory disease in the 12 months prior to the index date.
group.bmj.com on July 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from increase in the total number of asthma drug date, and (4) current use of steroids prior prescriptions in the four 90-day periods prior to the index date. Smoking status, BMI, and to the index date (table 3) . duration of asthma were not included in the final model since they did not materially influence the risk estimates.
 - 
The adjusted relative risk estimates of ipSubjects who died of pulmonary causes were ratropium, theophylline, and multiple drug compared with those who survived. The con-users compared with users of salmeterol were trols were randomly selected from the base 7.9 (95% CI 1.4 to 44.6), 1.1 (95% CI 0.2 to population and matched with the cases by age, 7.4), and 2.2 (95% CI 0.3 to 17.5), respectively. sex, and calendar time (year of first preThe independent effects of other variables scription). Variables adjusted in a conditional were derived from the conditional logistic logistic model were (1) number of prescriptions model (using arbitrarily chosen and predefined for asthma drugs in the three months prior to categories for number of asthma drug prethe index date, (2) number of outpatient visits scriptions and number of practice visits). The in the prior 12 months, (3) whether or not the relative risk estimate of those who had 10 or patient had been admitted to hospital due to more asthma drug prescriptions compared with asthma in the 12 months prior to the index those who had four or fewer prescriptions, adjusted for study drug exposure, number of general practice visits, prior steroid use, and of cases without COPD, it was not possible to interpret a conditional logistic regression model * More than one study drug started during the 16-week period of follow up (four deaths ipratropium bromide and theophylline, one death ipratropium bromide and salmeterol).
controlling for the presence of the risk factor An additional question addressed in the in salmeterol users is low and no higher than * Reference group.
that for users of theophylline and ipratropium. * * In the 3 months prior to the index date
The randomised clinical trial of Castle et ‡ In the 12 months prior to the index date al 1 and our observational study were similar with respect to some of the design characteristics. Both followed asthma patients who were newly treated with salmeterol for a 16-did an unconditional logistic regression analysis, restricted only to the 21 cases and 41 week follow up period, both studies had comparison groups (salbutamol in the clinical trial, controls with COPD or emphysema. The age (<55, 55-59, 60+ years) and sex adjusted ipratropium bromide and theophylline in our study), and both accepted the clinical diagnosis relative risk estimates for first time users of ipratropium bromide, theophylline and mul-made by the GP. However, a direct comparison of our results with the findings of the clinical tiple drug users compared with first time users of salmeterol were 1.8 (95% CI 0.4 to 9.6), trial needs some interpretation.
The clinical trial took place in 1990-1 and 3.0 (95% CI 0.4 to 22.4), and 1.3 (95% CI 0.2 to 9.6), respectively. our study covered an observation period from 1992-5. Our study focused on patients thought Further adjustment for number of drug prescriptions, number of practice visits, and to have more severe asthma, and there was likely to be somewhat fewer patients with whether or not the patient had been admitted to hospital in the year prior to the index date "severe" asthma involved in the clinical trial than in our study. 1 Many of the subjects in did not materially influence the results from this model. the clinical trial were judged by the general practitioner to have mild (17%) or moderately severe (65%) asthma. However, 91% were receiving a agonist, 69% an inhaled steroid, and Discussion Based on the recommendations of the British 43% other drugs for asthma prior to initiation of a study drug. Thus, the severity of asthma in Thoracic Society, 4 a first time prescription for salmeterol, ipratropium bromide, or theo-the clinical trial may not have been substantially different from that in our study. Finally, it is phylline is indicated for patients with asthma which is not yet well controlled by a com-important to emphasise that in the clinical trial there were subjects who were over 64 years of bination of a short acting agonist and an inhaled steroid. These guidelines led us to age while our study included only subjects of less than 65 years of age. select patients treated for the first time with these drugs as comparison groups in our study.
We restricted our study to asthma patients below 65 years of age because younger subjects The results support the proposition that the three drugs were usually prescribed according are more likely to have a firm and well documented diagnosis of asthma. Older patients are to the guidelines. Eighty percent of the recipients were receiving at least two other anti-more likely to have overlapping pulmonary as well as cardiovascular diseases which can conasthma drugs prior to initiating additional treatment with one of the study drugs. The results tribute to a deterioration of their respiratory condition. also show that the addition of a study asthma drug to the prior treatment was regularly preThe pulmonary mortality rates over a period of 16 weeks for patients in the clinical trial 1 ceded by worsening of symptoms prior to initiation of the new drug therapy, as reflected were 18/4704 person-years (3.8/1000 personyears) for salmeterol treated patients and 4/ in a considerable increase in the number of prescriptions for other asthma drugs in the 2361 (1.7/1000 person-years) for salbutamol treated patients. In the current study the pulpreceding three months (table 3) .
The results also show that the number of monary mortality rate for salmeterol users was 5/2795 person-years (1.8/1000 person-years), asthma drug prescriptions, the number of visits to general practice, and admission to hospital a rate which is similar to the mortality rate for salbutamol users in the clinical trial. This for respiratory problems in the year prior to the index date, as well as the presence of over-finding is consistent with the proposition that the threefold increased mortality in salmeterol lapping respiratory diseases such as COPD or emphysema, are strong independent predictors users compared with salbutamol users observed in the clinical trial may have been a chance for pulmonary deaths in subjects with asthma in this study population ( BMJ 1993; 306:1034-7. an acute asthma exacerbation as a "cause" of 2 Bunney R. Study too small to detect increase in deaths (letter) . BMJ 1993; 306:1610. asthma mortality has been discussed 3 Sears MR, Taylor DR. Increased deaths during salmeterol elsewhere. 
